Financial Performance Summary

Q2 FY27 Financial Highlights (Year-over-Year):

  • Total Income: ₹1,005.75 million vs ₹795.80 million in Q2 FY26, up 26%
  • EBITDA: ₹363.17 million vs ₹249.66 million in Q2 FY26, up 45%
  • EBITDA Margin: 36.7% vs 31.7% in Q2 FY26
  • PAT: ₹149.50 million vs ₹88.28 million in Q2 FY26, up 69%
  • PAT Margin: 15.1% vs 11.2% in Q2 FY26

H1 FY27 Financial Highlights (Year-over-Year):

  • Total Income: ₹1,893.09 million vs ₹1,530.72 million in H1 FY26, up 24%
  • EBITDA: ₹678.47 million vs ₹496.22 million in H1 FY26, up 37%
  • EBITDA Margin: 36.3% vs 32.8% in H1 FY26
  • PAT: ₹277.96 million vs ₹180.03 million in H1 FY26, up 54%
  • PAT Margin: 14.9% vs 11.9% in H1 FY26

Operational Performance Metrics

Q2 FY27 Operational Highlights:

  • Total tests: 2.32 million vs 2.20 million in Q2 FY26, up 5%
  • Total Patients: 0.42 million vs 0.38 million in Q2 FY26, up 12%
  • Tests per patient: 5.50 vs 5.83 in Q2 FY26
  • Average Revenue per test: ₹427 vs ₹357 in Q2 FY26, up 19%
  • Average Revenue per patient: ₹2,348 vs ₹2,083 in Q2 FY26, up 13%

H1 FY27 Operational Highlights:

  • Total tests: 4.42 million vs 4.13 million in H1 FY26, up 7%
  • Total Patients: 0.80 million vs 0.71 million in H1 FY26, up 12%
  • Tests per patient: 5.53 vs 5.78 in H1 FY26
  • Average Revenue per test: ₹422 vs ₹367 in H1 FY26, up 15%
  • Average Revenue per patient: ₹2,335 vs ₹2,120 in H1 FY26, up 10%

Management Commentary

Ms. Ritu Mittal, Joint Managing Director & CEO, commented on the results:

  • Suraksha continued its strong growth momentum in Q2 FY27, delivering healthy growth across the business
  • Performance was supported by sustained growth in patient and test volumes
  • Improving contributions from centers commissioned over past quarters which are progressively maturing
  • Company expanded network during quarter with five new centers (two hub centers and three spokes centers)
  • Expansion aligns with strategy of building clusters and increasing density around them
  • Strengthened presence across West Bengal while laying groundwork for expansion into newer markets
  • Suraksha Genomics focused on building presence and strengthening growth trajectory
  • Genomics believed to have potential to emerge as meaningful contributor over coming years
  • Focus remains on driving sustainable growth through existing network, improving contribution of maturing centers, and pursuing disciplined expansion across newer markets

Company Background

Suraksha Diagnostic Limited is:

  • Largest integrated diagnostic chain in East India
  • Leading provider of integrated solutions in pathology and radiology testing, and medical consultation services
  • Operates in states of West Bengal, Bihar, Assam and Jharkhand
  • Central reference laboratory accredited by College of American Pathologists
  • 4 laboratories hold National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation
  • 6 advanced diagnostic centers accredited by National Accreditation Board for Hospitals & Healthcare Providers (NABH)

Investor Relations Contact

MUFG Intime India Private Limited

  • Mr. Omkar Bagwe: omkar.bagwe@in.mpms.mufg.com
  • Sumeet Khaitan: sumeet.khaitan@in.mpms.mufg.com